Table 3.

Association of CXCL9 serum levels and physical performance at Visit 3 and changes in physical performance and bone mineral density (BMD) from Visit 3 to Visit 4

	Β	95% CI	p
Walking speed
M1	− 0.097	− 0.137, − 0.057	< 0.001
M2	− 0.064	− 0.105, − 0.024	0.002
M3	− 0.058	− 0.097, − 0.018	0.005
M4	− 0.038	− 0.078, 0.003	0.072
Chair stand
M1	− 0.615	− 0.935, − 0.295	< 0.001
M2	− 0.255	− 0.583, 0.073	0.129
M3	− 0.203	− 0.526, 0.119	0.218
M4	− 0.014	− 0.343, 0.314	0.933
Δ walking speed
M1	− 0.061	− 0.125, 0.002	0.060
M2	− 0.046	− 0.110, 0.017	0.157
M3	− 0.047	− 0.113, 0.018	0.158
M4	− 0.052	− 0.120, 0.016	0.139
Δ chair stand
M1	− 1.089	− 1.560, − 0.617	< 0.001
M2	− 1.005	− 1.494, − 0.516	< 0.001
M3	− 1.051	− 1.552, − 0.550	< 0.001
M4	− 1.098	− 1.624, − 0.571	< 0.001
Δ BMD in total hip
M1	− 0.015	− 0.031, 0.001	0.067
M2	− 0.014	− 0.030, 0.003	0.110
M3	− 0.012	− 0.029, 0.005	0.152
M4	− 0.012	− 0.029, 0.006	0.190
Δ BMD in femur neck
M1	− 0.009	− 0.024, 0.007	0.266
M2	− 0.007	− 0.023, 0.009	0.412
M3	− 0.005	− 0.022, 0.012	0.559
M4	− 0.004	− 0.021, 0.013	0.640

M1, unadjusted; M2, age-, race-, and site-adjusted; M3, M2 + BMI and PASE; M4, M3 + CRP, IL-1β, IL-6, and TNFα